Skip to main content
Premium Trial:

Request an Annual Quote

Iconix Pharmaceuticals Licenses Cal-Berkeley Data Mining Applications

NEW YORK, April 23 --  Iconix Pharmaceuticals of Mountain View, Calif., today announced that it has gained exclusive license to data mining tools created by Laurent El Ghaoui of the University of California, Berkeley.


Financial details were not provided.


The company will apply algorithms developed by El Ghaoui to its Drug Signatures brand library of biomarkers for toxicity and mechanism of action. El Ghaoui is an associate professor of electrical engineering at Berkeley.

Iconix Pharmaceuticals, a five-year-old spinoff from Microcide Pharmaceuticals of Mountain View, Calif., recently announced that it would provide the Center for Drug Evaluation and Research of the FDA with research access to its flagship DrugMatrix system, a collection of genomic and chemical data. The company's Drug Signatures library is based on the DrugMatrix system.
The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.